Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab for relapsed/refractory transformed aggressive lymphoma
DRKS00023793Phase 2Terminated
- Sponsor
- University Medical Center Mainz
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL) and transformed lymphoma, sponsored by University Medical Center Mainz. Started Jan 2021; status: terminated.
02
Drugs
tafasitamabrituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)transformed lymphoma
Beyond the preview
Go deeper on DRKS00023793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023793.